Taboada Rodrigo Gomes, Arruda Almeida Maria Fernanda, Santiago Karina Miranda, Carraro Dirce Maria, Nunes Warley Abreu, Diniz Alessandro Landskron, Felismino Tiago Cordeiro, de Jesus Victor Hugo Fonseca
Department of Medical Oncology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Department of Radiology, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
J Gastrointest Cancer. 2025 Jan 13;56(1):42. doi: 10.1007/s12029-024-01140-5.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor response to chemotherapy. High-frequency microsatellite instability (MSI-H) is a rare biological phenomenon in conventional PDAC, being more frequently described in tumors with medullary or mucinous features.
In this manuscript, we report the case of a patient with an MSI-H pancreatic carcinoma with medullary features (medullary carcinoma of the pancreas-MCP) that achieved a complete pathological response after neoadjuvant modified FOLFIRINOX. Additionally, we summarize the available evidence on the clinical, pathological, and molecular features of patients with MCP, along with survival outcomes.
MCPs present significant sensitivity not only to immune checkpoint inhibitors, but also to systemic chemotherapy and that the latter treatment modality should not be overlooked. They also present different pathological and molecular features compared with conventional PDAC, meaning they should be considered a separate pathological entity.
胰腺导管腺癌(PDAC)是一种侵袭性恶性肿瘤,对化疗反应不佳。高频微卫星不稳定(MSI-H)在传统PDAC中是一种罕见的生物学现象,在具有髓样或黏液特征的肿瘤中更常被描述。
在本手稿中,我们报告了1例具有MSI-H且伴有髓样特征的胰腺癌(胰腺髓样癌-MCP)患者,该患者在新辅助改良FOLFIRINOX治疗后达到了完全病理缓解。此外,我们总结了关于MCP患者的临床、病理和分子特征以及生存结果的现有证据。
MCP不仅对免疫检查点抑制剂具有显著敏感性,对全身化疗也敏感,且不应忽视后一种治疗方式。与传统PDAC相比,它们还具有不同的病理和分子特征,这意味着它们应被视为一个独立的病理实体。